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Background: The analysis of phenotypic characteristics onMycobacterium tuberculosis
(MTB)-specific T cells is a promising approach for the diagnosis of active tuberculosis
(aTB) and for monitoring treatment success. We therefore studied phenotypic changes
on MTB-specific CD4T cells upon anti-tuberculosis treatment initiation in relation to the
treatment response as determined by sputum culture.
Methods: Peripheral blood mononuclear cells from subjects with latent MTB infection
(n = 16) and aTB (n = 39) at baseline, weeks 9, 12, and 26 (end of treatment) were
analyzed after intracellular interferon gamma staining and overnight stimulation with
tuberculin. Liquid sputum cultures were performed weekly until week 12 and during 4
visits until week 26.
Results: T cell activation marker expression on MTB-specific CD4T cells differed
significantly between subjects with aTB and latent MTB infection with no overlap
for the frequencies of CD38pos and Ki67pos cells (both p < 0.0001). At 9 weeks
after anti-TB treatment initiation the frequencies of activation marker (CD38, HLA-DR,
Ki67) positive MTB-specific, but not total CD4T cells, were significantly reduced
(p < 0.0001). Treatment induced phenotypic changes from baseline until week 9 and
until week 12 differed substantially between individual aTB patients and correlated with
an individual’s time to stable sputum culture conversion for expression of CD38 and
HLA-DR (both p< 0.05). In contrast, the frequencies of maturation marker CD27 positive
MTB-specific CD4T cells remained largely unchanged until week 26 and significantly
differed between subjects with treated TB disease and latent MTB infection (p= 0.0003).
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Discussion: Phenotypic changes of MTB-specific T cells are potential surrogate
markers for tuberculosis treatment efficacy and can help to discriminate between aTB
(profile: CD38pos, CD27low), treated TB (CD38neg, CD27low), and latent MTB infection
(CD38neg, CD27high).
Keywords: TAM-TB assay, tuberculosis, treatment monitoring, Mycobacterium tuberculosis-specific T cells, serial
sputum culture, biomarker
INTRODUCTION
Novel diagnostic tools for improved detection of active
tuberculosis (aTB) and for monitoring TB treatment are urgently
required to succeed in the WHO END TB strategy, which—
in the abscence of an efficacious MTB vaccine - sets the
ambitious target of a world free of tuberculosis by 2030 (1).
Recent studies have highlighted the diagnostic potential of a
flow cytometry based approach to detect and differentiate aTB
disease from latent Mycobacterium tuberculosis (MTB) infection
(LTBI) via phenotypic and/or functional characterization of
MTB-specific T cells in adults and children (2–12). These “T cell
activation and maturation marker assays” (TAM-TB assay) are
sputum-independent, use easy-to-collect peripheral blood and—
in contrast to the traditional immunodiagnostic Tuberculin
skin test or Interferon gamma release assays (13)—allow highly
specific detection of aTB (3, 5). TAM-TB assay results have
been correlated with MTB loads in sputum (4, 9), with disease
severity and with lung tissue destruction (4). Our previous study
showed highly specific detection of childhood aTB in an endemic
setting (3), potentially superior to sputum culture. Furthermore,
TB treatment initiation decreases activation marker expression
on MTB-specific CD4T cells, probably reflecting the decrease
of mycobacterial burden in vivo (5); which would make this a
promising candidate marker for assessing TB treatment success.
While liquid culture and PCR are held to be the most
sensitive tools to detect MTB, their widespread implementation
for diagnosis and treatment monitoring is hampered by practical
and methodological problems. Firstly, since these methods
function by direct detection of the pathogen, they often remain
false negative in paucibacillery aTB patients (14–16), and those
where aTB lesions do not have access to the airways. As a
consequence, TB treatment is often started on a presumptive
diagnosis (17). Secondly, culture and PCR have shortcomings for
monitoring of the TB treatment response. MTB culture methods
have low sensitivity for unfavorable outcome and low positive
predictive value estimates (18). The GeneXpert PCR shows a lag
of positivity most likely due to detection of dead bacilli (19).
The current treatment duration is that of a “one-size-fits-all” 6-
months drug regimen without modifications based on treatment
response monitoring. Past trials conducted by the MRC East
Africa, and the more recent fluoroquinolone phase 3 studies,
have demonstrated that more than 80% of TB patients will
achieve cure after only 4 months of treatment (20–23). However
to introduce a 4-months treatment as a blanket approach, it
will be essential to discriminate between aTB patients who
achieve cure already after 4 months and those in need of longer
treatment. Sequential sputum bacterial load measurements by
culture have been tested in this regard, but have insufficient
sensitivity for detection of unfavorable treatment outcome on
an individual basis (19, 24). Together, these shortcomings in
mycobacteriological detection methods can impede accurate
diagnosis of aTB, meaningful TB treatment monitoring and
safe individualized treatment (21–23). The novel TAM-TB assay
approach could potentially improve TB diagnosis and treatment
monitoring; and hence help to overcome some of the challenges
affecting diagnosis solely based on the direct detection of MTB
bacilli in sputum. A prerequisite, herefore is a more detailed
understanding of the relationship between TAM-TB assay results,
the MTB infection status, and mycobacterial treatment response.
Here, we have therefore studied activation (CD38, HLA-
DR, and Ki67) and maturation (CD27) marker profiles on
IFNγ+ MTB-specific CD4T cells in subjects with LTBI, and in
aTB patients (25) before and after TB treatment initiation in
comparison to the mycobacteriological treatment response. The
patients were tightly monitored using MGIT culture on a weekly
basis until week 12 and on 4 additional time points until the end
of treatment at week 26 and showed no relapse during a 6months
follow-up after the end of treatment.
MATERIALS AND METHODS
Study Populations, Study Samples, and
Ethics Statements
HIVneg adult patients with culture confirmed aTB were enrolled
at two clinical sites in Tanzania (NIMR-MMRC, Mbeya, and
KCRI, Moshi) within the Panacea-TB MAMS treatment study
(Table 1, Figure 1; clinicaltrials.gov identifier NCT01785186)
(26). Four experimental treatments or the standard TB treatment
were given for 12 weeks, followed by 8 weeks of standard
treatment (rifampicin, isoniazid, pyrazinamide, and ethambutol)
and by standard dose rifampicin and isoniazid to complete
TABLE 1 | Demography of study subjects.
PanACEA HISIS
Gender (Male/Female) 30/9 0/16
Median Age (Range) 34.4 (19.2–65.4) 32 (17.9–38)
Median BMI (Range) 19.2 (15.2–41.6) not determined
HIV status (+/–) 0/39 0/16
AFB sputum smear positivity grade (1/2/3) 3/10/26 Not applicable
Median Days to Positivity Baseline (Range) 3.5 (1–7.5) Not applicable
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FIGURE 1 | Diagram of study subjects, time points and TAM-TB analyses. Peripheral blood mononuclear cell samples from aTB patients (n = 39) were collected at
baseline, at week 9, 12, and 26 after TB treatment initiation and subjected to TAM-TB assay analyses. The numbers of missing samples and those excluded due to
none responsiveness to the positive control antigen SEB (“poor quality”) are indicated for each time point. PBMC samples (n = 16) from HIV- IGRA+ subjects were
collected during the HISIS cohort study.
26 weeks of treatment. All study participants received further
follow-up for 6 months after end of treatment by telephonic
interviews and site visits. Of the patients included in this sub-
study, 25 were in either one of the experimental treatment arms,
whereas 14 subjects received the standard treatment. None of the
patients relapsed during this 6-months follow-up. The protocol
was approved by independent ethics committees of the sponsor,
the trial sites, and the regulatory authorities of Tanzania and
South Africa. Additional samples from HIVneg IGRA+ healthy
female bar workers from the HISIS study (27) were included
as LTBI controls (n = 16). The HISIS study was conducted
at the NIMR-MMRC in compliance with national guidelines
and institutional policies, and informed consent was obtained
in accordance with the Declaration of Helsinki. The study was
approved by the local ethic board at Mbeya (FWA no. 00002469)
and the National Ethic Board at the National Institute forMedical
Research (FWA no. 00002632).
TAM-TB Assay
Cryopreserved Peripheral Blood Mononuclear Cell (PBMC)
samples from aTB patients (n = 39, Figure 1) from baseline,
9, 12, and 26 weeks were analyzed using the TAM-TB assay
approach. PBMC samples from subjects with LTBI (n = 16)
were included as additional controls. PBMCs were stimulated
overnight at 37◦C and 5% CO2 with Purified Protein Derivative
(PPD, 10µg/ml, Serum Staten Institute), SEB (0.6µg/ml, Sigma-
Aldrich) as a positive control, or no added peptide as negative
control in the presence of Brefeldin A (BFA, final concentration
5µg/ml, Sigma) and the costimulatory antibodies anti-CD49d
(L25, BD) and anti-CD28 (L293, BD). Cells were stained with
anti-CD38 BV785 (clone HIT2, Biolegend), anti-CD4 APC
(clone 13B8.2, Beckmann Coulter), anti-CD27 ECD (clone
1A4CD27, Beckmann Coulter), and anti-HLA-DR APC-H7
(clone G46-6, Beckmann Dickinson), followed by fixation and
permeabilization using FoxP3 Perm/Fix buffer and diluent
(eBioscience), and then stained intracellularly using anti-IFNγ
FITC (clone B27, BD Pharmingen), anti-Ki67 BV421 (clone
B56, BD Pharmingen), and anti-CD3 APC-A700 (clone UCHT1,
Beckmann Coulter). Cells were acquired on a CytoFlex Flow
cytometer (Beckman Coulter). Data analysis was performed
using FlowJo_V10. MTB-specific CD4T cell responses were
defined by a frequency of ≥0.03% of IFNγ+ CD4T cells after
PPD stimulation and by ≥2-fold increase over the negative
control. Furthermore, a cell count of greater than 25 IFNγ+
CD4T cell events had to be recorded. Samples with no response
to the positive control antigen Staphylococcal enterotoxin B
(SEB) were excluded from the analyses (n= 17). Pestle and Spice
software (28)were used to analyze combinatorial expresssion of
the four phenotypic markers on IFNγ+ MTB-specific CD4T
cells.
Bacteriological Assessments
Patients submitted sputum during weekly visits until week 12,
and at weeks 14, 17, 22, and 26. Sputum was decontaminated
with NaCl-OH, and cultured in liquid media; the mycobacterial
growth indicator tube (Bactec MGIT960), and on Löwenstein-
Jensen (LJ) solid medium (22). The primary study endpoint was
time from treatment initiation to the first of two consecutive
negative weekly sputum cultures without an intervening positive
or contaminated culture in liquid media.
Statistical Analysis
The Statistical analysis was performed using GraphPad prism
software version 6. The tests used are indicated in the Figure
Legends.
RESULTS
T Cell Activation Marker Expression
Profiles on MTB-Specific CD4T Cells
Differentiate Between aTB and LTBI
At time of diagnosis, all aTB patients had detectable MTB-
specific CD4T cell responses upon PPD re-stimulation (median:
0.22%, range 0.03–4.3%). None-stimulated controls showed no or
very little background in IFNγ+ T cells (median: 0.008%, range
0.0–0.066%). SEB stimulated controls showed high frequencies
of IFNg+ CD4T cells (median: 1.92%, range: 0.6–9.3%). High
frequencies of MTB-specific CD4T cells expressed the activation
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FIGURE 2 | Representative dot plots for phenotypic characterization of MTB-specific CD4T cells. Shown are dot plots for active TB (A), 12 weeks into TB treatment
(B) and Latent TB Infection (C). Dot plots are gated on CD4T cells showing IFNγ (x-axis) and activation (CD38, HLA-DR, and Ki67) and maturation (CD27) marker
staining (y-axis) without stimulation (upper panel) and after PPD stimulation (lower panel). IFNγ+ MTB-specific CD4T cells are indicated (red box). The cut-off for the
expression of each phenotypic marker is indicated as a black line.
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markers CD38 (median: 71%, Figure 3, representative dot plots
in Figure 2), HLA-DR (median: 49.3%) and Ki67 (median:
17.5%) with a predominance of CD27low cells (median: 91.3%),
upon PPD stimulation. TAM expression on MTB-specific CD4T
cells differed significantly and showed no overlap for the
frequencies of CD38pos and Ki67pos cells between aTB and LTBI
(both p < 0.0001). Frequencies of CD27high and HLA-DRpos
cells also differed (both p < 0.0001), but showed greater overlaps
between aTB and LTBI. Receiver Operating Characteristic (ROC)
curve analysis between aTB and LTBI (Supplementary Figure 1)
confirmed that the frequency of CD38pos and Ki67pos MTB-
specific CD4T cells differentiated best between aTB and LTBI
[Area under the Curve (AUC) = 1] with a defined cut-off of
31.55% for CD38 and 3.7% for Ki67 (Supplementary Figure 1).
T Cell Activation Marker Expression
Profiles On MTB-Specific CD4T Cells
Change Rapidly Upon TB Treatment
Initiation
Frequencies of activated MTB-specific CD4T cells declined
dramatically from pre-treatment to W9 post-treatment
(p < 0.0001, Figure 3), while CD27high cell frequencies remained
largely unchanged (p = 0.8). These treatment-induced changes
varied substantially between individuals and were exclusively
observed in the MTB-specific T cell compartment, but not in
the non-specific CD4T cells (Figures 4A–D, Ki67 not shown).
The numeric data for the underlying Figure 4 is provided in
Supplementary Table 1. Consequently the changes in CD38
and HLA-DR expression until week 9 differed significantly
between MTB-specific and total CD4T cells (p < 0.0001 for
both markers, Figures 4E,F). Only comparatively moderate
changes were observed between W9 and W26 for CD38pos and
HLA-DRpos cell frequencies. The median frequency of Ki67pos
cells declined further to 1.5% (p = 0.01) between W12 and
26, whereas the median frequency of CD27low cells remained
unchanged between before and at the end of treatment (median:
91%, Figures 3B,D). Using SPICE analyses (28) combinatorial
changes of the 4 phenotypic markers on MTB-specific CD4T
cells were analyzed (Figure 5). The pie chart arcs show that
TB treatment induced substantial reductions in MTB-specific
T cell frequencies co-expressing the activation markers CD38,
HLA-DR, and Ki67 in different combinations as shown.
CD38 and CD27 Expression Phenotypes
Differentiate 3 MTB Infection States: Active
TB Disease, Treated TB, and Latent MTB
Infection
We next addressed the question whether and to what degree
the expression of activation and maturation markers on MTB-
specific CD4T cells correlate with one another and analyzed data
FIGURE 3 | Phenotypic profiles of MTB-specific CD4T cells in subjects with aTB, after TB treatment initiation and during LTBI. The frequency of MTB-specific CD4T
cells expressing the activation markers CD38 (A), Ki67 (B), HLA-DR (C), and the maturation marker CD27 (D) is shown on the y-axis for pulmonary TB patients
(purple circles) at baseline, 9, 12, and 26 weeks (x-axis) after TB treatment initiation. Subjects with latent MTB infection were included as controls (green diamonds).
MTB-specific CD4T cells were characterized after PPD stimulation. Statistical analyses were performed using the Mann-Whitney test. Median values, interquartile
range and p-values below 0.05 are indicated.
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FIGURE 4 | Detection of dynamic changes in CD38 and HLA-DR expression upon TB treatment initiation on MTB-specific, but not total CD4T cells. The frequency of
T cells expressing the activation markers CD38 and HLA-DR (y-axis) are shown for MTB-specific CD4T cells (A,B) and for total CD4T cells (C,D) before and at 9 and
12 weeks after treatment for each subject. MTB-specific CD4T cells were characterized after PPD stimulation. The slopes of the activation marker expression on
MTB-specific and on total CD4T cells were compared for CD38 (E) and HLA-DR (F) between baseline and week 9 (n = 29). Statistical analyses for paired data were
performed using the Wilcoxon-signed rank paired test. None-paired data analyzed using the Mann-Whitney test. P-values below 0.05 are indicated.
from aTB patients before and after TB treatment (n= 109 subject
visits, Figure 6). The frequency of all the activation marker
positive cells correlated with each other (all p < 0.0005). The
strength of correlation varied; CD38 and HLA-DR expression
correlated most strongly (Spm Rho = 0.76). The correlation of
Ki67 with either CD38 orHLA-DRwas comparatively weak (Spm
Rho = 0.35 and 0.33, respectively). A weak inverse correlation
was detected for the frequencies of CD27high cells with HLA-
DRpos (data not shown, both p < 0.05). In contrast, frequencies
of CD27high MTB-specific CD4T cells did not correlate with
the frequencies of CD38pos and Ki67pos cells (Figure 6D and
data not shown, p = 0.79 and p = 0.4, respectively).
Hence, simultaneous assessment of CD38 and CD27 holds most
information on TB disease and treatment status. Indeed, by
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FIGURE 5 | SPICE analyses for in-depth phenotypic profiling of MTB-specific CD4T cells. Shown are SPICE pie charts visualizing the mean frequency for each of the
16 possible phenotypic profiles of MTB-specific CD4T cells. The arcs indicate the proportion of cells that express CD27 (red), CD38 (green), HLA-DR (light blue)
and/or Ki67 (dark blue). The time point or LTBI infection status is indicated below each pie chart.
assessing only these two markers, the phenotypic characteristics
of MTB-specific CD4T cells at week 26 still differed from
LTBI with median frequencies of 28.8 and 12.1% for CD27high
(p = 0.0003) and CD38pos cells (p = 0.008), respectively. Hence,
phenotypic profiles differed significantly between aTB (profile:
CD38pos, CD27low), treated TB (CD38neg/pos, CD27low), and
LTBI (CD38neg, CD27high).
Treatment Induced Reductions in TAM
Expression Profiles on MTB-Specific CD4T
Cells Reflect Declining Bacterial Burden in
Sputum
Using the cut-off of < 31.55% CD38pos MTB-specific CD4T
cells to define LTBI, 37.5% (12 of 32) and 51.4% (18 of
35) of aTB patients had a TAM-TB profile consistent with
“LTBI” at W9 and W12 post-treatment, respectively. To address
whether such a phenotypic profile—determined at a single
post-treatment time point—indicates in vivo mycobacterial
clearance, we compared the time to last culture-positive result
from these patients with this “cured TAM-TB assay profile”
to those without such a TAM-TB profile. The two groups
did not differ (p = 0.58, data not shown) and those with a
“cured signature” still included 5 and 4 subjects, who were
still culture positive at or after W9 and W12, respectively.
Similar results were obtained using a more stringent cut off of
<19.7% CD38pos MTB-specific CD4T cells, which defined the
lower quartile of CD38pos cells at W12 (p = 0.26). Hence, a
“cured” TAM-TB signature measured at a single post-treatment
time point was not suggestive for clearance of viable bacteria
in sputum nor did it differentiate rapid from slow treatment
responders.
We next addressed whether changes in the frequencies of
T cell activation marker positive MTB-specific CD4T cells
between baseline and W9; and between baseline and W12
were linked to treatment-induced bacterial clearance using
the primary PanACEA study endpoint—time to stable culture
negativity. 32 of 39 subjects had TAM-TB results at baseline
and at W12 and/or W9 and thus the slope for the change in
expression of the individual TAMs after treatment initiation
could be determined. 15 of these 32 subjects also had an
accurate endpoint determination of ≤ 4 weeks between the
last positive and stable culture conversion (Figure 7). In the
other 17 subjects, determination of the accurate time to
culture conversion was compromised due to increasing rates
of culture contamination as treatment progressed—a common
phenomenon (29). These either did not reach stable culture
conversion or had large gaps between the last positive and
stable culture conversion and hence were excluded from analyses.
Taking into consideration baseline and W12 results, the slope
of decline in expression of CD38 (p = 0.0045, Rho = 0.7)
and HLA-DR (p = 0.02, Rho = 0.61) on MTB-specific CD4T
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FIGURE 6 | Correlation analysis of activation and maturation marker expression on MTB-specific CD4T cells. The proportion of IFNγ+ MTB-specific CD4T cells
expressing activation and maturation markers after stimulation were plotted for CD38 and Ki67 (A), CD38 and HLA-DR (B), Ki67 and HLA-DR (C), CD38 and CD27
(D) on the y- and x-axis, respectively for samples from subjects with aTB from before and after treatment initiation (n = 109). The Spearman’s rank test was used for
statistical analysis.
cells correlated with the time to stable culture conversion
(Figures 8A,B). Likewise, similar correlations were detected
when considering measurements at baseline and week 9 (n =
13 subjects, CD38: p = 0.015, Rho = 0.67; HLA-DR: p = 0.007,
Rho = 0.72, Figures 8C,D). No such correlations were detected
for CD38 and HLA-DR expression on total CD4T cells (data not
shown).
DISCUSSION
Substantial reductions in the expression of activation markers
on MTB-specific CD4T cells were observed at W9 into TB
treatment for most patients. In contrast, expression of these
markers on total CD4T cells remained comparable to pre-
treatment values, showing that TB treatment-induced changes
in T cell activation status are specific to the MTB-specific T
cell compartment. Individual patients varied substantially in
the early reduction in MTB-specific CD4T cell activation until
week 9 and week 12; and for both of these time intervals,
the degree of change in activation correlated well with the
mycobacterial response. Our data therefore provide evidence
that early changes in TAM expression profiles on MTB-specific
CD4T cells reflect clearance of viable mycobacteria in vivo. These
TAM-TB profiles may therefore serve as a surrogate marker
for treatment efficacy, as originally proposed by Adekambi
et al. (5) and now further substantiated in more aTB patients
with more precisely determined time to culture conversion.
This immunological approach therefore bypasses the issues
associated with the collection of sputum specimen (e g., in
young children, after TB treatment initiation) and increased
culture contamination rates as treatment progresses (29); which
renders treatment monitoring by serial cultures difficult and
often imprecise on a per person level, as was observed in our
patient subset. It is noteworthy, that all tested TB patients
responded to the MTB antigen PPD, therefore enabling the
determination of the activation status on MTB-specific CD4T
cells.
Shortening treatment is a major objective of TB drug
development and has been tested in 4 recent studies (20–23);
the majority (at least 80%) of patients treated in these trials
for only 4 months had been cured without relapse within the
defined follow up of 18 months; but nevertheless the trials
were declared unsuccessful due to high relapse rates in the
4 months regimens. While speculative at this point, a TAM-
TB assay approach based treatment-monitoring algorithm could
therefore potentially help to personalize TB treatment duration
by discrimination of patients who respond well to TB treatment
marked by a substantial reduction in MTB-specific CD4T cell
activation—and those who do not.
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FIGURE 7 | Sequential MGIT culture results. Sequential MGIT culture results from 17 study visits from week 0 to week 26 (x-axis) are shown for each subject with a
TAM-TB assay result from baseline and/or at week 9 and/or week12 (n = 32). The upper and lower line graphs indicate culture results from subjects with ≤ 4 (n = 15)
and ≥4 weeks (n = 17) between the last positive and stable culture conversion, respectively. Red dots indicate a MTB positive culture result, green dots a negative
culture result, and gray dots indicate a contaminated sample. Dark green squares indicate stable culture conversion defined as the first of two consecutive culture
negative results. Dark red square*: last culture positive sample before 2 consecutive culture negative samples.
The dynamic changes in expression of T cell activation
markers observed upon treatment initiation contrasted with
the minor changes observed for the maturation marker
CD27. We assessed, which combination of markers are most
informative on treatment and disease/infection status. Consistent
with previous results (5), expression of CD38 differentiated
best between aTB and LTBI. The three activation markers
correlated with one another and thus the determination of
one activation marker—CD38—might suffice to differentiate
active TB from LTBI and to monitor the treatment response.
No correlation was detected between expression of CD38 and
CD27 and the latter best differentiated treated TB at W26
from LTBI. Hence, simultaneous assessment of CD38 and
CD27 expression on MTB-specific CD4T cells, can help to
differentiate between three MTB infection/disease states; (1)
aTB—defined by high expression of activation markers, but
low CD27 expression; (2) LTBI—defined by low expression
of activation markers and high expression of CD27 and
(3) treated TB—defined by low expression of activation
markers and continuously low CD27 expression. Our data
therefore support the concept that phenotypic characteristics
of pathogen-specific T cells may not only differentiate between
active TB and LTBI, but may also detect past episodes of
pathogen activity, which were resolved through treatment or
naturally.
Previous reports on CD27 expression on MTB-specific CD4T
cells also showed no substantial increase by 26 weeks of treatment
(6). However, at 12 months after the end of TB treatment it
appears to revert to levels characteristic for LTBI (8). It could
be that residual TB disease activity at the end of TB treatment
and during LTBI, might contribute to such a CD27low profile,
as suggested by a recent positron emission tomography (PET-
CT) study. This study showed persistent, active lesion activity
in the majority of cured TB patients even until 6 months
after TB treatment (30). A large range of bacterial loads and
metabolic activity in MTB lesions (31–33) has also been observed
in non-human primates with LTBI consistent with a broad
spectrum between LTBI, treated and active disease (34, 35). We
had previously reported on a HIV seroconverter where CD27
downregulation on MTB-specific T cells preceded active TB
Frontiers in Immunology | www.frontiersin.org 9 September 2018 | Volume 9 | Article 2247
Ahmed et al. Tuberculosis Treatment Monitoring by TAM-TB Assay
FIGURE 8 | Changes in TAM expression profiles on MTB-specific CD4T cells upon treatment initiation reflect declining bacterial burden in sputum. A correlation
analysis between time to stable culture conversion and the slope of CD38 and HLA-DR marker expression dynamics on IFNγ+ MTB-specific CD4T cells is shown for
the time interval from baseline to week 12 (A,B, n = 15), and from baseline to week 9 (C,D, n = 13), respectively, for subjects with accurately defined time point of
less than 5 weeks between the last positive MGIT culture result and stable culture conversion. The Spearman’s rank test was used for statistical analysis.
diagnosis by 6–9 months (2). It would therefore be of great
interest to better define the range of expression of phenotypic
markers on MTB-specific T cells and other host response
markers (36–38) in relation to the presence and dynamics
of TB lesions in vivo in subjects with LTBI and in patients
after treatment initiation (30) with systematic follow up on
active TB disease progression, and treatment failure and relapse,
respectively.
It is known that males account to 65% of aTB patients
globally (39). Our LTBI control group consisted only of females,
which raised the concern whether gendermight have confounded
our results. To address this question, males (or females) were
excluded in a sub-group analysis (Supplementary Figure 2);
there was no overlap of CD38 and Ki67 in subjects with
LTBI and aTB, when considering only females (p < 0.0001).
Further, no gender-associated difference in the TAM-TB profile
at baseline was detected, whereas significant reductions in T cell
activation marker expression—but not for CD27 expression—
were induced by TB treatment regardless of gender. Hence
there was no evidence that gender alone influenced the TAM-
TB profile of MTB-specific CD4T cells in our study. It
is however noteworthy that males had significantly higher
frequencies of proliferating (Ki67+) MTB-specific CD4T cells
and a trend for increased expression of CD38 at 12 weeks
post treatment initiation (p = 0.09) compared to females
(data not shown). The latter finding is “consistent” with
another finding of the Panacea-TB MAMS treatment study;
females cleared mycobacteria significantly faster upon treatment
initiation as compared to males (unpublished results). Hence,
gender-associated differences in activation marker profiles of
MTB-specific CD4T cells at 12 weeks after treatment initiation
probably reflect gender-related differences in the rate of
mycobacterial clearance.
Limitations in this study were the lack of available X-ray
scores as well as disease severity assessment. We were also
not able to study the effect of HIV infection on TAM-TB
assay profiles during treatment monitoring, because our cohort
recruited exclusively HIV negative patients. HIV infection is
associated with increased levels of systemic T cell activation
(40, 41). Another study investigated the effect of HIV on MTB-
specific CD4T cell activation, andmaturation, showing only little
influence (7). Larger studies in well-characterized cohorts need
to clarify the influence of these parameters on TAM-TB assay
results and their changes upon treatment initiation. While the
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need for flow cytometry and basic cell culture methods may
limit the use of this approach in resource poor settings, our
data show that more complex flow cytometry is in principle not
needed. We and others have previously shown that by using
whole blood this assay can be simplified substantially (2, 42).
Other methods assessing the MTB-specific cytokine secretion
upon whole blood stimulations may also allow specific diagnoses
of active TB (43), whereas monitoring the TB treatment response
using the latter approach so far appears less promising (44). The
measurement of soluble biomarkers in the blood without prior
stimulation also may hold valuable information on TB disease
and treatment status (45). The diagnostic value of these needs
further investigation.
In conclusion, our data on using phenotypic profiles of MTB-
specific CD4T cells as a surrogate marker for treatment efficiency
warrant further research and methodological simplification to
define its usefulness in standard clinical sttings and during TB
drug trials.
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